The critical appraisal of cost-effectiveness by health care payers and their nominated agencies have applied pressure on health care developers to review health economics and outcomes research (HEOR) earlier in their clinical development plans to gain optimal pricing and reimbursement.
At Axcellant, our team have supported organisations navigate through the UK National Institute of Clinical Excellence (NICE) Health Technology Assessment (HTA). We have also supported pricing and reimbursement research commissioned by the French Ministry of Health and Social Affairs and also modelling for agencies in the US and Asia.
Axcellant is excited to announce our participation at the European Association of Nuclear Medicine (EANM) Congress in Hamburg from October…
Marking a significant achievement in our ongoing efforts to advance medical device research, we have successfully concluded a PMCF study…
Initiating a clinical trial is akin to embarking on a voyage of discovery in the realm of medicine. This journey,…
Copyright @ 2025 Axcellant. Designed By Frantic